|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Improving the standard of lymph node retrieval after gastric cancer sur- gery显示文摘 | Hanna GB Amygdalos I Ni M | 2013 | Histopathology2013，63，3： | 1 |
| 2 | Improving the standard ofiymph node retrieval after gastric cancer surgery 显示文摘 | Hanna GB Amygdalos I Ni M | 2013 | Histopathology2013，63，3： | 1 |
| 3 | Transjugular insertion of biliary stents(TIBS)in two patients with malignant obstruction,ascites,and coagulopathy显示文摘 | Amygdalos MA Haskal ZJ Cope C | | 0，，02： | 1 |
| 4 | Performance Appraisal in Greek Public Sector显示文摘 | Charalampos Amygdalos Nikoleta Bara Georgios Moisiadis | 2014 | Procedia - Social and Behavioral Sciences2014，，： | 1 |
| 5 | Improving the standard of lymph node retrieval after gastric cancer surgery 显示文摘 | Hanna GB Amygdalos I Ni M | 2013 | Histopathology2013，63，3： | 1 |
| 6 | Improving the standard of lymph node retrieval after gastric cancer surgery显示文摘 | Hanna GB Amygdalos I Ni M | 2013 | Histopathology2013，63，3： | 1 |
| 7 | Targeted therapies in cholangiocarcinoma:light at the end of the tunnel?显示文摘The genetic landscape of cholangiocarcinoma(CCA)remains largely unexplored.It is one of the deadliest cancers(1),with the gold standard treatment for all anatomical forms(intrahepatic-iCCA,perihilar-pCCA and distal-dCCA)being surgical resection(with adjuvant capecitabine also recommended in the newest guidelines)(2,3).The importance of genetic markers in terms of postoperative and oncological outcomes is being increasingly recognized,but few actionable mutations have been identified so far(2,4).This is particularly pertinent for patients with advanced/irresectable disease,who rely on systemic therapy.Survival outcomes are poor in these patients[5-year survival up to 10%-(5)]and they would profit the most from novel,targeted therapies. | Iakovos Amygdalos Ulf Peter Neumann Sven Arke Lang | 2023 | Hepatobiliary Surgery and Nutrition2023，12，4： | 0 |
| 8 | Liver transplantation in malignant disease显示文摘Liver transplantation for malignant disease has gained increasing attention as part of transplant oncology.Following the implementation of the Milan criteria,hepatocellular carcinoma(HCC)was the first generally accepted indication for transplantation in patients with cancer.Subsequently,more liberal criteria for HCC have been developed,and research on this topic is still ongoing.The evident success of liver transplantation for HCC has led to the attempt to extend its indication to other malignancies.Regarding perihilar cholangiocarcinoma,more and more evidence supports the use of liver transplantation,especially after neoadjuvant therapy.In addition,some data also show a benefit for selected patients with very early stage intrahepatic cholangiocarcinoma.Hepatic epithelioid hemangioendothelioma is a very rare but nonetheless established indication for liver transplantation in primary liver cancer.In contrast,patients with hepatic angiosarcoma are currently not considered to be optimal candidates.In secondary liver tumors,neuroendocrine cancer liver metastases are an accepted but comparability rare indication for liver transplantation.Recently,some evidence has been published supporting the use of liver transplantation even for colorectal liver metastases.This review summarizes the current evidence for liver transplantation for primary and secondary liver cancer. | Sven Arke Lang Jan Bednarsch Zoltan Czigany Katharina Joechle Andreas Kroh Iakovos Amygdalos Pavel Strnad Tony Bruns Daniel Heise Florian Ulmer Ulf Peter Neumann | 2021 | World Journal of Clinical Oncology2021，12，8： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员